Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Maximizing Impact and Utility of Prognostic Gene Testing in Melanoma and Squamous Cell Carcinoma : Episode 1
Opinion
Video
Limitations and Challenges in Skin Cancer Staging Systems
Author(s):
An expert discusses the patient demographics and clinical features used in traditional staging and risk classification of melanoma and squamous cell carcinoma (SCC), examining how staging systems from organizations like the American Joint Committee on Cancer (AJCC) and National Comprehensive Cancer Network (NCCN) align in risk classification, the challenges of relying solely on clinical features for prognosis, and the importance of accurate risk staging in guiding treatment decisions for these cancers.
Video content above is prompted by the following:
- Discuss the patient demographics and clinical features that are included in traditional staging and risk classification of melanoma and SCC.
- Do the different staging systems, such as ones used by AJCC and NCCN, generally agree with regard to risk classification? Discuss some of the challenges with basing prognosis strictly on clinical features.
- What is the importance of accurate risk staging? How do treatment guidelines for melanoma and SCC differ based on the patient’s risk profile?
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Related Videos
Related Content
